70 results about "Nerve Diseases" patented technology

The invention relates to a multistage self-anchoring flexible deep brain electrical stimulation electrode and a preparation method thereof, and relates to the technical field of medical instruments. A bionic root system-octopus whisker composite framework including a main electrode base, a second-stage fractal arm and a third-stage self-anchoring tail end is adopted, intelligent materials such as carbon nano tube / PDMS composite fibers, temperature-sensitive PNIPAAm hydrogel and a degradable PLGA-gelatin composite material are fused, and a mechanical lock catch and biological fusion dual-anchoring mechanism is constructed. The distributed electrode array comprises platinum-iridium alloy, graphene / PDMS and a titanium nitride nano electrode, and cross-scale stimulation from the nuclear group level to the single cell level is achieved. The intelligent regulation and control system solves the problems of brain tissue displacement and chronic inflammation through a pressure feedback degradation and flexible interconnection technology. Compared with a traditional product, the contact area of the electrode is increased by 5-8 times, the stimulation precision reaches the single cell level, and the electrode is suitable for long-term deep brain stimulation treatment of nerve diseases such as Parkinson's disease and epilepsy and has remarkable clinical application value.

A polypeptide linker (2 to 21 amino acids) is connected to a carrier peptide based on the Ioop2 domain of lynx1. The carrier or transporter peptide may be further coupled via the polypeptide linker to a molecule of interest (MOI) or effector agent, such as a protein or protein domain or any other biomolecule (e.g., biomolecules having a molecular weight of 10kDa to 230 kDa). In some embodiments, the complex may be used therapeutically in targeting various neurological disease-causing cellular components.

A method of generating MSC-derived exosome populations may include collecting MSC containing material from living tissue, separating desired mononuclear cells from granulocytes, culturing to multiply the cells, separation of desired cells for further multiplication by washing non-adherent cells and culturing adherent cells, repeating as necessary to obtain a suitably pure population of MSCs, culturing the MSCs in culture media containing negative / healing active cytokines interleukin-4 (IL-4) and interleukin-10 (IL-10) and multifunctional cytokine TGF-ß, and isolating the MSC-derived exosome populations. Diverse MSC-derived exosome populations may be generated by altering the cytokine composition of the culture media. The MSC-derived exosome populations may be screened for effectiveness in treatment of Long Covid using in vitro, in vivo, and pre-clinical testing utilizing model organisms. The exosomes may be administered nasally. Successful MSC-derived exosome populations may be further subjected to patient trials to establish efficacy in treatment of Long Covid via nasal administration of the MSC-derived exosome populations to human subjects. Similar methodologies may be employed to establish efficacy of the MSC-derived exosome populations for treatment of other diseases and conditions related to the central nervous system, spinal cord injury, or neurological diseases, such as Alzheimer disease.

The present technology related to a genus of compounds which are prodrugs of arimoclomol. The present technology further relates to compositions comprising the same and methods of treating neurological diseases and disorders by administering said compounds.

The application discloses a cistema brain-computer interface-minimally invasive whole brain nerve signal acquisition and closed-loop control system based on a cerebrospinal fluid channel and a method thereof. The system comprises a flexible cistema interface array, an ultra-wideband wireless energy and data synchronous transmission module, a nerve signal analysis and decoding module, a self-adaptive closed-loop control module and a system integrated control platform. The flexible cistema interface array is implanted in a cerebrospinal fluid cavity in a minimally invasive manner to acquire multi-brain region nerve signals; and the ultra-wideband transmission module realizes energy supply and high-speed bidirectional communication between an implanted body and an extracorporeal device. The application solves the problems of a large trauma, limited coverage and poor signal quality of an existing invasive interface, has the advantages of minimally invasive, wide area coverage, high signal quality and good integration, and is suitable for diagnosis and treatment of neurological diseases such as epilepsy suppression and post-stroke motor function reconstruction.

Provided herein are antibodies and antigen-binding domains that specifically bind to human CD98 and their use in, for example, transport across the blood brain barrier (BBB). Among others, also provided herein are conjugates comprising these anti-CD98 antibodies and antigen-binding fragments, such as the conjugates with GLP-1R agonists, and their uses in, for example, treating or preventing neurological diseases or disorders and / or metabolic diseases or disorders.

The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.

A dynamic neuropsychological assessment tool according to an embodiment utilizes speech recognition, speech synthesis and machine learning to assess whether a patient is at risk for a neurological disorder, such as Alzheimer's disease. The dynamic neuropsychological assessment tool enables self-administration by a patient. The tool performs pre-test validation operations on the test environment, test equipment, and the patient's capability for performing the test at that time. The tool also enables dynamic modification of a questionnaire presented to the patient while the patient completes the questionnaire. Also provides the dynamic modification of which tests to present the patient with. The modification can be rule based or modified by a provider. The dynamic neuropsychological assessment tool enables providers and administrators to modify and improve tests and validate them using machine learning based on previously completed assessments and results.

Provided are multispecific antibodies or antigen binding fragments thereof comprising at least one first antigen-binding region capable of binding specifically to pyroglutamate amyloid-β and a second antigen-binding region capable of binding specifically to transferrin receptor (TfR). Also provided are methods of treating or detecting a neurological disorder and / or delivering a therapeutic or diagnostic agent across the blood-brain barrier. Also described are nucleic acids encoding the antibodies, vectors comprising the nucleic acids, recombinant host cells comprising the nucleic acids and / or vectors, and methods of producing the multispecific antibodies or antigen binding fragments thereof.

Combination therapies comprising oxytocin and gonadotropin releasing hormone are provided. The combinations can be used to treat aging-related neurological diseases or disorders. In addition, downstream effectors of OXT-GnRH combination, including hypothalamic stem / progenitor cells-derived EVs and vesicles containing or loaded with PTMS, can be used to treat aging-related neurological diseases or disorders.

The present invention relates to the use of a culture medium-based method for inducing the specific differentiation of dental stem cells into dopaminergic neurons. The purpose of the present invention is to develop cell applications for treating degenerative neurological diseases and drugs related to the diseases.

The present invention addresses the problem of providing an agent for preventing or treating amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Huntington's disease (HD), spinocerebellar ataxia (SCA), aging-related degenerative or neurological disease, brain aging, or diseases associated with brain aging, as well as a more stable antibody that exhibits an effect of preventing or treating these diseases, Alzheimer's disease (AD), or frontotemporal lobar degeneration (FTLD). A human monoclonal antibody that specifically binds to human HMGB1, wherein the human monoclonal antibody (anti-human HMGB1 antibody) comprises a heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 each consisting of a specific amino acid sequence and a light chain CDR1, light chain CDR2, and light chain CDR3 each consisting of a specific amino acid sequence, is used as an agent for preventing or treating ALS, PD, HD, SCA, aging-related degenerative or neurological disease, brain aging, or diseases associated with brain aging. An antibody in which the light chain complementarity determining region (CDR) 3 of the anti-human HMGB1 antibody has been modified is used.

Osmotic blood-tissue barrier opening offers a promising approach to surmounting challenges posed by the blood-brain barrier in the treatment of brain cancer and neurological diseases. By enhancing permeability of any blood-organ barrier, enabling precise targeting, reducing toxicity, being less invasive, and potentially accommodating larger therapeutic molecules, osmotic blood-organ barrier opening represents a valuable strategy in the fight against diseases such as brain cancer and neurological diseases.

The present invention provides, in part, protein-drug conjugates comprising an anti-transferrin receptor (e.g., human transferrin receptor) antigen binding protein (e.g., scFv, Fab) conjugated to a molecular load (e.g., a polynucleotide, liposome, or lipid nanoparticle) for delivery of the molecular load to a target tissue (e.g., brain or muscle). Methods of treating various diseases or disorders, such as neurological or muscular diseases, with the conjugates are provided.

The present invention relates to methods, kits, and compositions for testing a sample from a subject and determining: i) if said subject is A / A, A / C, or C / C at position 4444 in the Glutamyl-prolyl-tRNA synthetase 1 (EPRS1) gene or mRNA, and / or ii) if said subject expresses only the 1482T version, only the 1482P version, or both the 1482T and 1482P versions, of the EPRS1 protein; and / or iii) if said subject is m6A methylated or m6A unmethylated at A4355 and / or A4464 in said EPRS1 mRNA; and determining that the subject has hypomyelinating leukodystrophy (HLD) or other neurological condition. The present application also relates to a bioinformatic pipeline to assess if m6A-distal single-nucleotide-variations (m6Ad-SNV) affect methylation of DRACH sites.

The present invention relates to a diagnostic composition comprising at least one peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 (VDELERIRRSILPYGDSMDRIEKDR), SEQ ID NO: 2 (GGAGSLGAGGAFGEA), SEQ ID NO: 35 (GPAGPPGHPGPPGPR), SEQ ID NO: 4 (EGLITLTELADSLLS), SEQ ID NO: 5 (EFQYLTGGLIEPQVH), SEQ ID NO: 6 (SSHMLTDTKTGLHFN), SEQ ID NO: 7 (FIPGPPGPPGPPGPR), SEQ ID NO: 8 (INEAIEQGTIDKALV), SEQ ID NO: 9 (AFGEAAGDRGPYGTDI) and SEQ ID NO: 10 (LITLTELADSLLSRL). Furthermore, the present invention relates to an in vitro method for detecting the presence or absence of a disease selected from the group of bullous pemphigoid, Parkinson's disease, and a neurological disorder comprising testing the binding of at least one peptide as identified in any of the preceding claims for binding to autoantibodies obtained from a subject suspected of suffering from one of said diseases.

A neural disease diagnosis system based on space-time attention and dynamic domain adaptation belongs to the technical field of cross-modal medical data adaptive analysis. It solves the technical problem that there is an urgent need for a new system that can simultaneously fuse multi-modal information, model multi-scale space-time features, and have dynamic domain adaptation capability to improve the accuracy and generalization ability of multi-site neural disease intelligent diagnosis. The system comprises: a data preprocessing module for extracting standardized time series of individual brain regions from fMRI time series data; a dual-channel feature encoding network module for obtaining global features through an attention mechanism; a feature fusion and classification module, wherein a main task classifier performs a main task to predict whether a testee has a neural disease, and a domain task classifier performs a domain task to predict the site to which the testee belongs; and a dynamic balance training module for adjusting the dynamic balance of the main task and the domain task through a dynamic balance control strategy.

The present invention addresses the problem of providing an agent for preventing or treating amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Huntington's disease (HD), spinocerebellar ataxia (SCA), aging-related degenerative or neurological disease, brain aging, or diseases associated with brain aging, as well as a more stable antibody that exhibits an effect of preventing or treating these diseases, Alzheimer's disease (AD), or frontotemporal lobar degeneration (FTLD). A human monoclonal antibody that specifically binds to human HMGB1, wherein the human monoclonal antibody (anti-human HMGB1 antibody) comprises a heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 each consisting of a specific amino acid sequence and a light chain CDR1, light chain CDR2, and light chain CDR3 each consisting of a specific amino acid sequence, is used as an agent for preventing or treating ALS, PD, HD, SCA, aging-related degenerative or neurological disease, brain aging, or diseases associated with brain aging. An antibody in which the light chain complementarity determining region (CDR) 3 of the anti-human HMGB1 antibody has been modified is used.

A method for identifying a cerebral edema or a cerebral microhemorrhage in a subject, the method including providing a sample obtained from the subject, comprising a level of one or more biomarkers, wherein the one or more biomarkers comprises one or more GLX-related GAGs, one or more GLX-related PGs, one or more GLX-related GPs, one or more GLX-related GLs, one or more GLX-related GCs, or one or more fragments thereof, or any combination of the aforementioned biomarkers; measuring or detecting the level of the one or more biomarkers in the sample; comparing the level of the one or more biomarkers measured or detected to a reference level for the one or more biomarkers; and identifying the subject as having a cerebral edema or a cerebral microhemorrhage if the level of the one or more of the biomarkers measured or detected from the sample are different than the reference level for the one or more biomarkers.

Novel cyclic peptides, cyclic peptide conjugates and compositions containing them for treating neurological diseases in a subject include an Odorranalectin (OL) sequence or modified OL sequence as a scaffold and a biologically active peptide or protein and / or therapeutic agent conjugated thereto. Methods of treatment of neurological diseases are based on intranasal delivery of a cyclic peptide or cyclic peptide conjugate as described herein. Combinatorial libraries that include a plurality of cyclic peptides have also been developed and can be used to screen for a ligand(s) for a receptor of interest.

Glucose dendrimers synthesized using a hypercore and glucose monosaccharide-based branching units significantly enhances accumulation in neurons in the brain and in retina when administered in vivo, as compared with dendrimers without glucose monosaccharide-based branching units such as PAMAM. Compositions of glucose dendrimers conjugated with one or more therapeutic, prophylactic or diagnostic agents to prevent, treat, or diagnose a disease or disorder in a subject in need thereof, and methods of use thereof, have been developed. The compositions are particularly suited for treating and / or ameliorating diseases or disorders associated with diseased neurons in the eye or the brain. Methods of treating a human subject having or at risk of a neurological disease or disorder are provided.

The invention belongs to the technical field of medicines, and relates to 4-methylquinazoline derivatives, and a preparation method, a pharmaceutical composition and application thereof. The 4-methylquinazoline derivative is a compound shown in a formula (I) or a pharmaceutically acceptable salt thereof, is a PI3K inhibitor, and can be used for preventing and / or treating diseases related to PI3K activity, such as tumors, autoimmune diseases, kidney diseases, cardiovascular diseases, inflammation, metabolism / endocrine dysfunction or nerve diseases. # imgabs0 #

This invention relates to 2-amino-4-methylquinazoline compounds, their preparation methods, uses, and pharmaceutical compositions. Specifically, it provides a compound represented by Formula I, which is a phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor that can be used to prevent and / or treat diseases related to PI3Kδ activity, such as tumors, autoimmune diseases, immunodeficiency diseases, inflammation, kidney diseases, cardiovascular diseases, metabolic / endocrine disorders, or neurological diseases.

The invention discloses a spinal degenerative nerve disease focus positioning method based on a multi-scale convolutional neural network, and belongs to the technical field of biomedical image processing. According to the method, through multi-scale image input, subdivision label construction and a multi-model training strategy, in combination with the target detection capability of YOLOv8, refined positioning and evaluation of the spinal degenerative nerve disease are realized, and a quantitative auxiliary tool is provided for clinical diagnosis. The core innovation of the method lies in a multi-dimensional label system and label shielding training, and the detection precision of serious lesions is improved.

Novel cyclic peptides, cyclic peptide conjugates and compositions containing them for treating neurological diseases in a subject include an Odorranalectin (OL) sequence or modified OL sequence as a scaffold and a biologically active peptide or protein and / or therapeutic agent conjugated thereto. Methods of treatment of neurological diseases are based on intranasal delivery of a cyclic peptide or cyclic peptide conjugate as described herein. Combinatorial libraries that include a plurality of cyclic peptides have also been developed and can be used to screen for a ligand(s) for a receptor of interest.

Provided herein is a dendrimer complex comprising a 2-deoxyglucose (2DG) dendrimer and a neuroactive agent conjugated to an outer surface of the dendrimer. The dendrimer complex may further include one or more imaging agents and / or radioligands conjugated to an outer surface of the dendrimer. Such complexes are useful in methods for detecting or treating neurological diseases or disorders.

The invention provides a TMS stimulation device which comprises a transcranial magnetic stimulation circuit and a control unit, the control unit is used for controlling the transcranial magnetic stimulation circuit to generate continuous and repeated magnetic field stimulation signals, and a small, light and high-safety household machine type can be designed to adapt to the characteristic that cranial nerve diseases need to be treated periodically and repeatedly. The action range of the stimulation probe can be effectively narrowed, a brain target stimulation area can be accurately positioned, and the problems that due to the fact that the stimulation range of the probe of an existing transcranial magnetic therapeutic instrument is too large, irrelevant brain areas except a therapeutic target area are stimulated, the therapeutic effect is not ideal, and various side effects are possibly caused are solved.

The invention belongs to the field of chemical pharmacy. Relates to 4-methylquinazoline derivatives, and a preparation method, a pharmaceutical composition and application thereof. The 4-methylquinazoline derivative is a compound shown in a formula (I) or a pharmaceutically acceptable salt thereof, is a PI3K inhibitor, and can be used for preventing and / or treating diseases related to PI3K activity, such as tumors, autoimmune diseases, kidney diseases, cardiovascular diseases, inflammation, metabolism / endocrine dysfunction or nerve diseases.

This invention relates to compositions for the prevention or treatment of degenerative neurological diseases, comprising a compound that induces the expression of the anti-aging gene klotho as an active ingredient. The compound of this invention, expressed by chemical formula 1, exhibits excellent efficacy in increasing the expression level of the Klotho gene, a gene related to aging, and can be effectively used as a pharmaceutical composition or food composition for the prevention, improvement, or treatment of degenerative neurological diseases.

The present invention relates to a process for the industrial scale preparation of (3β,24S)-25,25,25-trifluoro-3-methyl-26,27-dinorergost-5-ene-3,24-diol, useful in counteracting the progression of highly disabling neurological diseases such as Alzheimer's, Parkinson's, and Huntington's disease, and having the structure shown below: The invention also relates to an improved method for the separation of two epimers that are obtained during the synthesis.